WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United ...

Kessler Topaz Meltzer & Check, LLP encourages Maravai investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/maravai- lifesciences-holdings-inc?utm_source=PR&utm_medium=link&utm_campaign=mrvi&mktm=r ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: RADNOR, Pa., March 31, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities ...

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to allegations of misleading statements and inadequate internal controls over financial reporting, particularly regarding revenue recognition and goodwill [3][4]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from August 7, 2024, to February 24, 2025 [3]. - Allegations include: 1. Lack of adequate internal controls over financial reporting related to revenue recognition 2. Inaccurate revenue recognition on certain transactions during fiscal 2024 3. Overstated goodwill 4. Misleading positive statements about the company's business and prospects [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 5, 2025, to participate in potential recovery [4]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

DEADLINE: May 5, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission- form/?id=139416&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MRVI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to s ...

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_f ...

RADNOR, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadlin ...

Core Viewpoint - Maravai LifeSciences has faced significant stock price declines due to concerns over its financial reporting and internal controls, leading to a class action lawsuit from investors [1][2][4]. Financial Reporting Issues - On March 18, 2025, Maravai warned investors against relying on its Q2 and Q3 2024 financial reports, stating they would be restated due to improper revenue recognition [3][6]. - The company acknowledged that its disclosure controls and procedures were ineffective, which contributed to the inaccuracies in financial reporting [3][6]. Stock Price Impact - Following the announcement on March 19, 2025, Maravai's shares fell nearly 6%, compounding a previous drop of 21% on February 25, 2025, when the company postponed its Q4 and FY 2024 earnings release [1][5]. - An analyst from Baird downgraded Maravai's rating from outperform to neutral and reduced the price target from $9 to $3 after the February announcement [5]. Class Action Lawsuit - A class action lawsuit has been filed against Maravai, representing investors who purchased securities between August 7, 2024, and February 24, 2025, alleging false and misleading statements regarding financial statements and internal controls [2][4]. - The lawsuit claims that Maravai failed to disclose crucial information about its financial reporting practices, which led to investor losses [4][5]. Revenue Recognition Concerns - Maravai is under scrutiny for potentially recording unearned revenues and overstating goodwill, with specific instances of revenue being inaccurately recognized by approximately $3.9 million in Q2 2024 [5][6]. - The company is currently assessing the adequacy of its internal controls over financial reporting, particularly concerning revenue recognition [6].

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action securities lawsuit due to alleged securities fraud impacting investors between August 7, 2024, and February 24, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the Company's business and prospects [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased Maravai securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=138831&fr ...